[go: up one dir, main page]

WO2024085824A1 - Agent anti-métastatique efficace sur des cellules de cancer de la prostate et convenant à une utilisation dans le traitement de ces maladies - Google Patents

Agent anti-métastatique efficace sur des cellules de cancer de la prostate et convenant à une utilisation dans le traitement de ces maladies Download PDF

Info

Publication number
WO2024085824A1
WO2024085824A1 PCT/TR2022/051215 TR2022051215W WO2024085824A1 WO 2024085824 A1 WO2024085824 A1 WO 2024085824A1 TR 2022051215 W TR2022051215 W TR 2022051215W WO 2024085824 A1 WO2024085824 A1 WO 2024085824A1
Authority
WO
WIPO (PCT)
Prior art keywords
antimetastatic
pharmaceutical composition
formula
prostate cancer
antimetastatic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2022/051215
Other languages
English (en)
Inventor
Zeliha GÖKMEN
Engin ULUKAYA
Remzi Okan AKAR
Original Assignee
İsti̇nye Üni̇versi̇tesi̇
İstanbul Üni̇versi̇tesi̇-Cerrahpaşa Rektörlüğü
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TR2022/015931 external-priority patent/TR2022015931A2/tr
Application filed by İsti̇nye Üni̇versi̇tesi̇, İstanbul Üni̇versi̇tesi̇-Cerrahpaşa Rektörlüğü filed Critical İsti̇nye Üni̇versi̇tesi̇
Priority to EP22947055.4A priority Critical patent/EP4384278A4/fr
Publication of WO2024085824A1 publication Critical patent/WO2024085824A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms

Definitions

  • the present invention belongs to the pharmacology technical field and relates to an antimetastatic agent and pharmaceutical compositions comprising these agents, which are effective in prostate cancer cells and can be used to treat diseases associated with these cancer cells or relieve symptoms caused by these diseases.
  • the prostate is the largest accessory gland of the male genital system and constitutes the initial part of the male urethra.
  • the prostate gland which is made partly of tubuloalveolar glands and partly of intermediate tissue filling between these glands, is 3 cm high, 4 cm wide, and 2 cm thick and has a large walnut size, and weighs about 18-20 grams.
  • the prostate gland is located in the lower part of the small pelvis (pelvis minor), behind the posterior border of the symphysis pubis, in front of the Ampulla Recti, above the Diaphragma Urogenitale and below the bladder.
  • the base (the side facing the bladder) of the prostate gland which is roughly cone-shaped, is up and the top facing the back is down.
  • the base of the prostate is continuous with the bladder where it is adjacent.
  • prostate cancer is the most frequently diagnosed cancer among men and the second most common cause of death.
  • Prostate cancer causes the patient to return to the clinic after a few years by spreading (by metastasizing) to other organs or lymph nodes other than the pelvic region. Therefore, the ability to metastasize is a very important (fatal) feature of prostate cancer.
  • Prostate cancer metastasis usually spreads to the bones or spine. In later stages, it can also metastasize to the lung, liver, distant lymph nodes, or brain.
  • existing cancer drugs are still insufficient in the treatment of patients with advanced, metastatic prostate cancer. Therefore, it is necessary to investigate strategies for synthesizing and treating stronger and more selective new drugs with fewer side effects for the treatment of metastatic prostate cancer.
  • Quinones are widely distributed in nature, and many clinically important antitumor drugs containing quinine, such as anthracyclines, mitoxantrone, and saintopin, show excellent anticancer activity. These anticancer agents are effective inhibitors of DNA topoisomerase, and it is generally known that the cytotoxicity of quinine analogues results from the inhibition of DNA topoisomerase-II. Quinine analogs can also induce the formation of a semiquinone radical, which can transfer an electron to oxygen to produce superoxide. This process is catalyzed by flavoenzymes such as NADPHcytochrome-P-450 reductase. Naphthoquinones are members of the quinone family and due to their anticancer and antitumor properties, many cancers are the subject of research and development to treat the disease and relieve the symptoms caused by these diseases.
  • quinine such as anthracyclines, mitoxantrone, and saintopin
  • prostate cancer which is one of the most common types of cancer among men, and in the treatment of symptoms of these diseases and the prevention of metastasis.
  • the present invention relates to an antimetastatic agent in which anticancer, antitumor, and antimetastatic properties against prostate cancer cells are determined by studies on PC-3, DU- 145, and LNCaP cell lines, known as the prostate cancer cell line.
  • the invention relates to an antimetastatic agent which may exhibit anticancer, antitumor, and antimetastatic properties against prostate cancer cells or which can be used as a drug substance in a pharmaceutical composition to relieve symptoms caused by these diseases.
  • the invention relates to an antimetastatic agent in which cytotoxic and antimetastatic effects are determined in prostate cancer cell lines for the technical field.
  • the invention relates in one aspect to an antimetastatic agent which is used to obtain pharmaceutical compositions which are used to relieve prostate cancer diseases or symptoms caused by these diseases.
  • the invention is an antimetastatic agent of Formula 2, which has cytotoxic and anticancer properties and anti -metastatic effects for prostate cancer cells, suitable for use in the treatment of diseases caused by cancer cells or in the prevention and elimination of metastasis caused by these cancer cells,
  • Formula 2 or the pharmaceutically acceptable salts, hydrates, solvates, polymorphs, optical isomers, geometric isomers, enantiomers, diastereomers of the said antimetastatic agent, or a mixture thereof.
  • the invention relates to pharmaceutical compositions comprising Formula 2 or acceptable salts, hydrates, solvates, polymorphs, optical isomers, geometric isomers, enantiomers, diastereomers, or a mixture thereof.
  • a preferred embodiment of the invention is that the pharmaceutical composition comprises an antimetastatic agent shown by Formula 2 or pharmaceutically acceptable salts, hydrates, solvates, polymorphs, optical isomers, geometric isomers, enantiomers, diastereomers of the said antimetastatic agent or a mixture thereof in the range of 1 pM to 10 pM.
  • a preferred embodiment of the invention is that the pharmaceutical composition comprises an antimetastatic agent shown by Formula 2 or pharmaceutically acceptable salts, hydrates, solvates, polymorphs, optical isomers, geometric isomers, enantiomers, diastereomers of the said antimetastatic agent or a mixture thereof in the range of 2.5 pM to 5 pM.
  • a preferred embodiment of the invention is that the pharmaceutical composition comprises at least one or more excipients.
  • a preferred embodiment of the invention is that the pharmaceutical composition comprises at least one other active ingredient.
  • a preferred embodiment of the invention is that the pharmaceutical composition comprises at least one selected from the group consisting of nucleoside analogues, antifloates, other metabolites, topoisomerase I inhibitors, anthracyclines, podophyllotoxins, taxanes, vinca alkaloids, alkylating agents, platinum compounds, antihormones, radiopharmaceuticals, monoclonal antibodies, tyrosine kinase inhibitors, rapamycin mammalian target inhibitors, immune system regulators, histodeacetylase inhibitors as other active ingredients.
  • the pharmaceutical composition comprises at least one antineoplastic agent and these are selected from a group consisting of cyclophosphamide, ifosfamide, temozolomide, capecitabine, 5-fluoro uracil, methotrexate, gemcitabine, pemetrexed, mitomycin, bleomycin, epirubicin, doxorubicin, etoposide, paclitaxel, irinotecan, docetaxel, vincristine, carboplatin, cisplatin, oxaliplatin, bevacizumab, cetuximab, gefitinib, imatinib, trastuzumab, denosumab, rituximab, sunitinib, zoledronate, abiraterone, anastrozole, bicalutamide, exemestane, goserelin, medroxyprogesterone, octre
  • Figure 1 shows the cell viability after 48 hours of administration of the antimetastatic agent at 0.6-40 pM dose range in PC-3, DU 145, and LNCaP cell lines by SRB assay.
  • Figure 2 shows the detection of apoptosis levels by flow cytometry after 12 and 24 hours of administration of the antimetastatic agent at doses of 2.5 5 and 10 pM in PC-3, DU 145, and LNCaP cell lines.
  • Figure 3 shows the EMT -related proteins by western blot method after 12 and 24 hours of administration of the inventive compound at 2.5, 5, and 10 pM doses in PC-3, DU 145, and LNCaP cell lines.
  • Figure 4 shows the qRT-PCR of the EMT-associated genes after 24 hours of administration of 2.5pM dose of the inventive compound to PC-3, DU 145, and LNCaP cells.
  • the subject of the invention belongs to the pharmacology technical field and it relates to an antimetastatic agent which is effective in prostate cancer cells and is suitable for use in the treatment of diseases caused by these cancer cells or the relief of the symptoms caused by these diseases, pharmaceutical compositions comprising these molecules and obtaining these molecules, and it is explained with examples that do not have any limiting effect only for a better understanding of the subject.
  • prostate cancer is defined as malignant tumoral formations that occur as a result of abnormal and uncontrolled proliferation of prostate gland cells, which are part of the male reproductive system.
  • the symptoms of the disease are not characteristic and usually, one of the complaints of difficulty in urinating, frequent urination, blood in the urine or semen, erection problems, pain during ejaculation, and involuntary weight loss can be experienced.
  • the stage of prostate cancer is not important and may be in the first, second, third, or fourth stages.
  • the "PC-3 cell line” is male human prostate cancer cells.
  • the PC3 cell line was formed in 1979 from Grade IV bone metastasis of prostate cancer in a 62-year-old white male. These cells do not respond to androgens, glucocorticoids, or fibroblast growth factors, but the results are influenced by the epidermal growth factors of the cells.
  • the PC-3 cell line is considered to be the standard prostate cancer cell line used in therapeutic research for prostate cancer.
  • the "DU 145 cell line” is a human prostate cancer cell line.
  • the DU-145 cell line was first isolated from the brain of a 69-year-old male patient with prostate disease. This cell line is suitable as a transfection host.
  • the DU145 cell line is considered to be the standard prostate cancer cell line used in therapeutic research for prostate cancer.
  • the "LNCaP cell line” is a cell line of human cells commonly used in the field of oncology.
  • LNCaP cells are androgen-sensitive human prostate adenocarcinoma cells derived from the left supraclavicular lymph node metastasis of a 50-year-old white male in 1977.
  • the LNCaP cell line is considered to be the standard prostate cancer cell line used in therapeutic research for prostate cancer.
  • the antimetastatic agent of the present invention will preferably be administered in the form of a pharmaceutical composition.
  • the antimetastatic agent of the invention may be included in the pharmaceutical composition as the drug substance or excipient.
  • treatment or treating means preventing, alleviation, improving or blocking at least one disorder that characterizes a pathological disorder in a subject threatened by or has a disorder.
  • "relief of symptoms” refers to all kinds of applications aimed at eliminating at least the symptoms and symptoms, that is, the etiology of diseases, even if the disease is not fully treated.
  • the "antimetastatic effect" is the activity of each of the therapeutic products that prevent the spread of cancer cells that have the characteristic of metastasis. Many deaths in cancer diseases are caused by cancer cells with metastatic activity, and reducing the metastatic activity of these cancer cells will allow the recovery rate of cancer diseases to increase and the development of symptoms caused by cancer diseases to be prevented.
  • the mesenchymal type cell markers mentioned in the invention and scientifically accepted are vimentin and N-cadherin, where the migration and invasion capacity of the cells is higher, apoptosis-resistant, and extracellular matrix production is increased.
  • the scientifically accepted epithelial cell marker mentioned in the invention which is a polarized cell type and is connected to the basal membrane, is E-cadherin.
  • Naphthoquinone is the class of organic compounds structurally associated with naphthalene as known in the art.
  • the naphthoquinone compound class has two isomers, mainly 1,2- naphthoquinone and 1,4-naphthoquinone compounds.
  • the antimetastatic agent of the invention contains the 1,4-naphthoquinone compound as a skeleton.
  • the 1,4-naphthoquinone compound is expressed as Formula 1 for greater clarity.
  • the antimetastatic agent of the invention may contain the compound naphthoquinone as a skeleton, but it has a structure that can cause a cytotoxic effect by reacting with the said cancer cells that can form a treatment for prostate cancer.
  • the antimetastatic agent of the invention may contain the compound naphthoquinone as a skeleton, but it has a structure that can cause a cytotoxic effect by reacting with the said cancer cells that can form a treatment for prostate cancer. This part, which ensures that the antimetastatic agent has a cytotoxic effect, is
  • naphthoquinone compounds have a cytotoxic effect on various cancer cells.
  • naphthoquinone compounds which are already known to have a cytotoxic effect on cancer cells, can easily enter into communication with prostate cancer cells, and to ensure that they have a high cytotoxic effect for these cells, a thio-crown-ether portion has been added and naphthoquinone compounds have been specifically configured for prostate cancer cells.
  • the innovative aspect of the invention is mainly related to the fact that the agent of the invention, which is known to have anticancer and antitumor effects, has antimetastatic activity.
  • an anticancer and/or antitumor agent, therapeutic molecule, or composition As known in the art, while the anticancer and/or antitumor properties of an antimetastatic agent, therapeutic molecule, or composition are known, whether an anticancer and/or antitumor agent, therapeutic and/or composition has antimetastatic activity or not arises as a result of research and development activities.
  • the present inventors have determined the antimetastatic efficacy of the structure shown in Formula 2 to provide a technical contribution in this direction for the related technical field.
  • the present inventors also share the results of testing and laboratory tests while providing these technical teachings for the related technical field.
  • the antimetastatic agent of the present invention is configured as Formula 2 to have an antimetastatic and cytotoxic effect on prostate cancer cells.
  • PC-3, DU-145, and LNCaP cell lines obtained by the procedures known in the art are used to determine the efficacy of the antimetastatic agent of the present invention for prostate cancer cells.
  • the antimetastatic agent of the invention was subjected to SRB viability testing for PC-3, DU 145, and LNCaP cell lines at doses of 0.6-40 micromoles (to be abbreviated to pM).
  • the SRB viability test is an indirect test that demonstrates viability based on total protein concentration in cells. The results of the said test are shared in Figure 1. According to the results of this test, the dose suppressing half of the viability (IC50) was 2.5 pM in the PC-3 cell line and 5 pM in DU 145 and LNCaP cell line. Viability was found to decrease in a dose-dependent manner. Apoptosis activity and stages of the antimetastatic agent of the invention were tested in flow cytometry using "Annexin V".
  • Annexin V is a phospholipid-binding protein that binds to phosphatidyl serine (PS) with high affinity and selectivity in the presence of calcium, as known in the art.
  • PS phosphatidyl serine
  • PS is predominantly located on the inner surface of the cell membrane facing the cytosol.
  • Annexin V is detected by flow cytometry, so that the apoptotic cell ratio is determined.
  • the results obtained here are shared in Figure 2. According to the results of this test, the antimetastatic agent was found to induce apoptosis in prostate cancer cell lines depending on dose and time.
  • the said molecule was found to increase the rate of late apoptotic cells to 93.61% in the PC-3 cell line; 24.38% in the DU 145 cell line; to 41.84% in the LNCaP cell line after 24 hours at a dose of 10 pM.
  • the present inventors subjected the cells to western blot and QRT-PCR applications to examine changes in target protein and mRNA expression in the cells after applying the antimetastatic agent of formula 2.
  • the target protein and mRNAs selected in the tests were selected to be associated with metastasis and the EMT process. The results of these tests are shared in the description and the figures.
  • the antimetastatic agent was subjected to a western blot test for PC-3, LNCaP, and DU-145 cell lines.
  • the results of this test are shared in Figure 3.
  • mesenchymal markers decrease at the protein level after formula 2 administration, while epithelial markers increase.
  • the antimetastatic agent increased the markers of epithelial character and reduced mesenchymal markers in human prostate cancer cell lines PC-3, DU 145, and LNCaP. This indicates that the antimetastatic agent of Formula 2 induces Mesenchymal-Epithelial Transformation (MET) in these cell lines, thus preventing the metastasis of prostate cancer cells. It is anticipated that the antimetastatic agent of Formula 2 carries out the naphthoquinone skeletal structure with the thio-crown-ether part.
  • MET Mesenchymal-Epithelial Transformation
  • the present inventors have determined the doses required for the antimetastatic agent of the invention to show metastatic activity for prostate cancer. Accordingly, the antimetastatic agent of the invention should be used in a range of 1 pM to 10 pM for prostate cancer. As seen in Figure 3, it is seen that the antimetastatic E-cadherin protein is increased in PC-3 and DU145 cell lines by the agent of the invention. In Figure 4, it is seen that the metastatic ZEB-1 gene is suppressed as a result of the administration of the 2.5 pM dose of the agent of the invention for 24 hours.
  • the antimetastatic e-cadherin protein was increased by the agent of the invention, while the metastatic ZEB-1 gene was suppressed by the agent of the invention, as can be seen in the tests performed on the agent obtained in the invention. Therefore, it has been determined that the agent according to the invention has antimetastatic properties.
  • the drug substance in the pharmaceutical composition is in the range of 1 pM to 10 pM as Formula 2. In the most preferred embodiment, the drug substance in the pharmaceutical composition is in the range of 2.5 pM to 5 pM as Formula 2.
  • An embodiment of the invention relates to pharmaceutical compositions having antimetastatic activity comprising Formula 2 or pharmaceutically acceptable salts thereof.
  • Formula 2 or pharmaceutically acceptable salts thereof may be prepared such that they are rich in an enantiomer.
  • the enantiomerically rich mixture is obtained by an enantiomer constituting, for example, at least 60%, or preferably 75%, 90%, 95%, or 99%, as the molar.
  • the mixture enriched from one enantiomer may be prepared such that it hardly contains the other enantiomer.
  • An embodiment of the invention relates to pharmaceutical compositions comprising Formula 2 or pharmaceutically acceptable salts thereof.
  • Formula 2 or pharmaceutically acceptable salts thereof may be prepared such that they are rich in a diastereomer.
  • the diastereomer-rich mixture is obtained by at least 60%, or preferably 75%, 90%, 95%, or 99% of an enantiomer as molar.
  • the mixture enriched from one diastereomer may be prepared such that the other diastereomer comprises virtually no diastereomer in one embodiment of the invention.
  • pharmaceutically acceptable hydrates, solvates, polymorphs, and optical isomers of the said Formula 2 may also be used.
  • An embodiment of the invention relates to pharmaceutical compositions suitable for use in the treatment of prostate cancer comprising Formula 2 or pharmaceutically acceptable salts thereof as the drug substance.
  • the said pharmaceutical compounds comprise at least one or more auxiliaries as well as drug substances according to the invention.
  • the pharmaceutical composition comprising Formula 2 or pharmaceutically acceptable salts thereof as the drug substance may comprise at least one other drug substance.
  • the pharmaceutical composition of the invention may be selected from a subgroup comprising, but not limited to, nucleoside analogues, antifloates, other metabolites, topoisomerase I inhibitors, anthracyclines, podophyllotoxins, taxanes, vinca alkaloids, alkylating agents, platinum compounds, antihormones, radiopharmaceuticals, monoclonal antibodies, tyrosine kinase inhibitors, rapamycin mammalian target inhibitors, immune regulators, histodeacetylase inhibitors, and other substances.
  • Anticancer agents may be selected from the group consisting of docetaxel, gemcitabine, imatinib, 5-fluorouracil, 9-aminocaptotesine, amine-modified geldanamycin, doxorubicin, paclitaxel, procarbazine, hydroxyurea, mesocyclone, cisplatin, and radionuclides.
  • the pharmaceutical composition comprising the antimetastatic agent of the invention can be of any form based on the preferred method of administration to a patient.
  • the composition comprising the antimetastatic agent of the invention may be formulated to be administered orally, for example in the form of liquid dispersions or aqueous or fatty suspensions, or the pharmaceutical composition may be formulated for parenteral administration, for example in the form of subcutaneous, intravenous, intramuscular, sternum, intraperitoneal, intradermal, intradermal or other infusion singles.
  • the pharmaceutical composition comprising the molecules of the invention may also be formulated for administration as a solution for administration by inhalation in the form of a spray tube or for administration by a respirator or nebulizer.
  • the pharmaceutical composition containing the antimetastatic agent of the invention is preferably administered to the patient transdermal, subcutaneous, intranasal, intravenous, intramuscular, intramuscularly, or by inhalation.
  • Embodiments are disclosed herein to include certain features/elements.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un agent qui présente des propriétés cytotoxiques et anti-cancéreuses, ainsi que des effets anti-métastatiques contre des cellules du cancer de la prostate, qui est approprié pour être utilisé dans le traitement de maladies provoquées par des cellules cancéreuses ou la prévention ou l'élimination de métastases provoquées par ces cellules cancéreuses, ou des sels, hydrates, solvates, polymorphes, isomères optiques, isomères géométriques, énantiomères, diastéréomères pharmaceutiquement acceptables dudit agent anti-métastatique ou un mélange de ceux-ci.
PCT/TR2022/051215 2022-10-19 2022-11-01 Agent anti-métastatique efficace sur des cellules de cancer de la prostate et convenant à une utilisation dans le traitement de ces maladies Ceased WO2024085824A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP22947055.4A EP4384278A4 (fr) 2022-10-19 2022-11-01 Agent anti-métastatique efficace sur des cellules de cancer de la prostate et convenant à une utilisation dans le traitement de ces maladies

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2022015931 2022-10-19
TR2022/015931 TR2022015931A2 (tr) 2022-10-19 Prostat kanseri̇ hücreleri̇ üzeri̇nde etki̇li̇ ve bu hastaliklarin tedavi̇si̇nde kullanilabi̇li̇r bi̇r anti̇metastati̇k etki̇ye sahi̇p bi̇r ajan

Publications (1)

Publication Number Publication Date
WO2024085824A1 true WO2024085824A1 (fr) 2024-04-25

Family

ID=90737996

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2022/051215 Ceased WO2024085824A1 (fr) 2022-10-19 2022-11-01 Agent anti-métastatique efficace sur des cellules de cancer de la prostate et convenant à une utilisation dans le traitement de ces maladies

Country Status (1)

Country Link
WO (1) WO2024085824A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000001047A (ko) * 1998-06-08 2000-01-15 박찬구 1,4-나프토퀴논과 1,3-부타디엔류를 이용하는 안트라퀴논류의제조방법
US20090247472A1 (en) * 2006-04-25 2009-10-01 Fluofarma Type 1, 4-naphtoquinone compounds, compositions comprising them and use of these compounds as anti-cancer agents
JP5339040B2 (ja) * 2008-08-25 2013-11-13 学校法人武庫川学院 新規ナフトキノン化合物およびその医薬用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000001047A (ko) * 1998-06-08 2000-01-15 박찬구 1,4-나프토퀴논과 1,3-부타디엔류를 이용하는 안트라퀴논류의제조방법
US20090247472A1 (en) * 2006-04-25 2009-10-01 Fluofarma Type 1, 4-naphtoquinone compounds, compositions comprising them and use of these compounds as anti-cancer agents
JP5339040B2 (ja) * 2008-08-25 2013-11-13 学校法人武庫川学院 新規ナフトキノン化合物およびその医薬用途

Similar Documents

Publication Publication Date Title
US20240261265A1 (en) Tinostamustine for use in treating ovarian cancer
US12303492B2 (en) Compounds for treating TNBC
TWI667021B (zh) 二氫檞皮素或其醫藥上可接受之鹽、或含有彼之組合物的醫藥用途
WO2009002553A1 (fr) Procédés de traitement d'un myélome multiple et de cancers résistants
HUP0302130A2 (hu) Kombinációs gyógyszerkészítmény és eljárás az előállításukra
JP2003528920A (ja) 血管損傷性活性を有する併用療法
KR20240073856A (ko) 스피로노락톤 및 아실풀벤의 조합을 이용한 암의 치료
US20240360247A1 (en) Compositions and methods for treatment of cancer
SK287762B6 (sk) Použitie aplidínu na prípravu farmaceutického prostriedku na liečenie rakoviny
TW201713328A (zh) 治療癌症之方法
WO2024085824A1 (fr) Agent anti-métastatique efficace sur des cellules de cancer de la prostate et convenant à une utilisation dans le traitement de ces maladies
EP4384278A1 (fr) Agent anti-métastatique efficace sur des cellules de cancer de la prostate et convenant à une utilisation dans le traitement de ces maladies
CA2946112C (fr) Therapie ciblee pour restaurer le transport de l'iode radioactif pour traiter le cancer de la thyroide
WO2021030404A1 (fr) Procédés et compositions pour traiter des malformations vasculaires
ES3030540T3 (en) Treatment of breast cancer using combination therapies comprising gdc-9545 and gdc-0077
TR2022015931A2 (tr) Prostat kanseri̇ hücreleri̇ üzeri̇nde etki̇li̇ ve bu hastaliklarin tedavi̇si̇nde kullanilabi̇li̇r bi̇r anti̇metastati̇k etki̇ye sahi̇p bi̇r ajan
WO2014028080A1 (fr) Traitement du cancer de la prostate et de néoplasmes hématologiques
CN111718328A (zh) 4-甲基-1h-二芳基吡唑类衍生物在制备抗肿瘤药物中的用途
WO2024085823A1 (fr) Nouvel agent thérapeutique à effet cytotoxique dans le cancer du sein triple négatif
RU2268729C2 (ru) Комбинированные терапии с использованием активности, повреждающей сосуды
KR20240072366A (ko) 펜타데칸산을 유효성분으로 포함하는 항암 보조제 및 이의 용도
KR20120006923A (ko) 암 치료 또는 예방용 약학 조성물

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2022947055

Country of ref document: EP

Effective date: 20231227

NENP Non-entry into the national phase

Ref country code: DE